• Logo
  • SBMUJournals

Circulating tumor DNA applications in treatment monitoring of metastatic colorectal cancer patients

Nesa Kazemifard, Amir Sadeghi, Behnaz Varaminian, Hamid Rezvani, Ahmad Ayadi, Ramin Talaie, Arfa Moshiri
51

Views

PDF

Abstract

Colorectal cancer is the third most common cancer worldwide. New cancer treatment strategies such as monoclonal antibodies against growth factor and angiogenesis receptors improved the overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC) patients. However, acquired resistance could happen after these therapies. Circulating tumor DNA (ctDNA) is the DNA fraction derived from tumor cells and could be applied as a non-invasive method for detecting tumor mutations before, during, and after therapies. Here, we reviewed most of the studies on the application of ctDNA as treatment monitoring in mCRC patients who receive different target therapies. Also, we compared ctDNA with other existing cancer-treatment monitoring methods.

 


Keywords

Circulating tumor DNA, Colorectal cancer, Treatment monitoring.

References

Yamauchi M, Urabe Y, Ono A, Miki D, Ochi H, Chayama K. Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients. Int J Cancer 2018;142:1418-26.

Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, et al. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 2017;23:2414-22.

Osumi H, Shinozaki E, Takeda Y, Wakatsuki T, Ichimura T, Saiura A, et al. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Med 2019;8:408-17.

Yamada T, Iwai T, Takahashi G, Kan H, Koizumi M, Matsuda A, et al. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. Cancer Sci 2016;107:936-43.

Siravegna G, Sartore-Bianchi A, Mussolin B, Cassingena A, Amatu A, Novara L, et al. Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Ann Oncol 2017;28:1302-8.

Boeckx N, Op de Beeck K, Beyens M, Deschoolmeester V, Hermans C, De Clercq P, et al. Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients. Clin Colorectal Cancer 2018;17:e369-79.

Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, et al. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Clin Cancer Res 2017;23:5416-25.

Song T, Mao F, Shi L, Xu X, Wu Z, Zhou J, et al. Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients. Clin Chem lab Med 2018;57:268-75.

Trojan J, Klein-Scory S, Koch C, Schmiegel W, Baraniskin A. Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer. Case Rep Oncol Med 2017;2017:6139634.

Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci 2017;18.

Osumi H SE, Mashima T, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, et al. Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer. Cancer Sci 2018;109.

Battaglin F, Ahcene Djaballah S, Lenz HJ. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer. Cancer Manag Res 2019;11:5911-24.

Passardi A, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, et al. Impact of second-line cetuximabcontaining therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Sci Rep 2017;7:10426.

Douillard JY, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, et al. Panitumumab–FOLFOX4 treatment and ras mutations in colorectal cancer. N Engl J Med 2013;369.

Van Helden EJ, Angus L, Menke-van der Houven van Oordt CW, Heideman DAM, Boon E, van Es SC, et al. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer. Mol Oncol 2019;13:2361-74.

Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget 2015;6:40360-9.

Xu JM, Wang Y, Wang YL, Wang Y, Liu T, Ni M, et al. PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 2017;23:4602-16.

Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 2016;7:13665.

Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov 2016;6:147-53.

Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26:731-6.

Braig F, Marz M, Schieferdecker A, Schulte A, Voigt M, Stein A, et al. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget 2015;6:12035-47.

Knebel FH, Bettoni F, da Fonseca LG, Camargo AA, Sabbaga J, Jardim DL. Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer. Front Oncol 2019;9:170.

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 2019;12:27.

Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, et al. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther 2018;18:251-66.

Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R, et al. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. Eur J Cancer 2017;75:245-58.

Greally M, Kelly CM, Cercek A. HER2: An emerging target in colorectal cancer. Curr Probl Cancer 2018;42:560-71.

Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open 2017;2:e000279.

Kanat O, Ertas H, Caner B. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World J Clin Cases 2018;6:418-25.

Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, et al. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer Cell 2018;34:148-62.

Wei Q, Zhang Y, Gao J, Li J, Li J, Li Y, et al. Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA. Clin Colorectal Cancer 2019;18:175-82.

Yakirevich E, Resnick MB, Mangray S, Wheeler M, Jackson CL, Lombardo KA, et al. Oncogenic ALK fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target. Clin Cancer Res 2016;22:3831-40.

Al-Salama ZT, Keam SJ. Entrectinib: first global approval. Drugs 2019;79:1477-83.

Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov 2016;6:36-44.

Byrne M, Saif MW. Selecting treatment options in refractory metastatic colorectal cancer. Onco Targets Ther 2019;12:2271-8.

Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, et al. Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget 2018;9:17756-69.

Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, et al. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut 2018;67:1484-92.

Wong AL, Lim JS, Sinha A, Gopinathan A, Lim R, Tan CS, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med 2015;13:57.

Zhang J, Babic A. Regulation of the MET oncogene: molecular mechanisms. Carcinogenesis 2016;37:345-55.

Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, et al. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. Br J Cancer 2017;117:347-52.

Jia J, Morse MA, Nagy RJ, Lanman RB, Strickler JH. cell-free DNA profiling to discover mechanisms of exceptional response to cabozantinib plus panitumumab in a patient with treatment refractory metastatic colorectal cancer. Front Oncol 2018;8:305.

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res 2016;76:4504-15.

Nikolaou S, Qiu S, Fiorentino F, Rasheed S, Tekkis P, Kontovounisios C. Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol 2018;22:481-98.

Sun X, Huang T, Cheng F, Huang K, Liu M, He W, et al. Monitoring colorectal cancer following surgery using plasma circulating tumor DNA. Oncol Lett 2018;15:4365-75.

Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut 2019;68:663-71.

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346.

Yu D, An G, Xu L. Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer. Clin Lab 2016;62:1947-53.

Yamada T, Matsuda A, Koizumi M, Shinji S, Takahashi G, Iwai T, et al. Liquid Biopsy for the Management of Patients with Colorectal Cancer. Digestion 2019;99:39-45.

Sun Q, Liu Y, Liu B, Liu Y. Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation. Am J Med Sci 2018;355:220-7.

Kidess-Sigal E, Liu HE, Triboulet MM, Che J, Ramani VC, Visser BC, et al. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget. 2016;7:85349-64.

Ma Z, Williams M, Cheng YY, Leung WK. Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer. Dis Markers 2019;2019:2673543.

Murray DH, Symonds EL, Young GP, Byrne S, Rabbitt P, Roy A, et al. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. J Cancer Res Clin Oncol 2018;144:1741-50.

Herbst A, Vdovin N, Gacesa S, Ofner A, Philipp A, Nagel D, et al. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer. Int J Cancer 2017;140:2134-44.

Symonds EL, Pedersen SK, Murray DH, Jedi M, Byrne SE, Rabbitt P, et al. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. Clin Epigenetics 2018;10:63.




DOI: https://doi.org/10.22037/ghfbb.v12i0.1812